Confirmed Pregnant: How Much More Levothyroxine, Starting When
A woman with a thyroid removed for cancer just found out she's pregnant. The disagreement isn't whether her levothyroxine needs to go up — every voice agrees it does — it's whether a fixed rule-of-thumb increase fits a patient with no thyroid tissue left to help her at all.
Amara J., a 33-year-old logistics coordinator, had a total thyroidectomy for papillary thyroid cancer four years ago and has been stable since on 125 micrograms of levothyroxine daily, her TSH holding at 1.4 μIU/mL at her last check two months ago. She called this week, three days late for her period and a positive home test in hand, asking what she should do about her thyroid medication before her first prenatal visit even happens. She has no other medical conditions and takes no other daily medications. Because she has no remaining thyroid tissue at all, every milligram of hormone in her body from this point forward will come from her pill, not from any residual gland compensating on its own.
Pregnancy increases levothyroxine requirements for essentially everyone with hypothyroidism, through rising estrogen-driven thyroxine-binding globulin, placental hormone effects, and increased maternal blood volume and metabolic clearance — and the standard teaching, drawn from Alexander and colleagues' foundational work on this exact question, is to increase the dose by roughly twenty to thirty percent as soon as pregnancy is confirmed, often taught as adding two extra doses a week rather than waiting for a scheduled lab to guide it, since the fetal neurodevelopmental window most sensitive to maternal hypothyroxinemia falls early, before a first-trimester TSH would typically even be drawn. But the size of that increase isn't uniform across causes. Loh and colleagues, separating hypothyroid pregnancies by etiology, found athyreotic women needing roughly a fifty percent increase against about sixteen percent for autoimmune hypothyroidism — patients with no functioning thyroid tissue at all need substantially more than patients with some remaining gland to lean on, since a partial gland can absorb some of the added demand on its own and an athyreotic patient's pill is the entire supply.
On the phone, deciding how much to raise the dose before any lab is drawn
I'd have her increase by roughly thirty percent starting today, not the standard twenty to thirty percent range's lower end. Alexander and colleagues established the general rule — about twenty-nine percent, taken as two extra doses a week — but Loh and colleagues later separated patients by etiology and found athyreotic women needing close to fifty percent against roughly sixteen for autoimmune hypothyroidism. She belongs to the first group, not the second. She has no thyroid tissue of her own to partially compensate the way a Hashimoto's patient with a still-present, if damaged, gland might.
I agree she needs more than the general population's rule-of-thumb increase, and I agree the timing can't wait for a scheduled first-trimester lab — the neurodevelopmental risk window from maternal hypothyroxinemia is earliest in pregnancy, often before a first visit would even happen. Where I'd push back slightly is on committing to a specific percentage over the phone without a baseline pregnancy TSH to anchor it.
You're citing the athyreotic subgroup data as though it gives us her specific number, but that data describes a group average need, not a guarantee for any one patient — raising her dose by a fixed thirty percent today without a baseline value risks either under-correcting for her specific requirement or overshooting it, and we won't know which until labs come back either way.
Both points are compatible if we treat today's increase as a bridge, not a final answer. Raise her now, at the higher end given her athyreotic status, specifically because the cost of under-treating during the earliest and most sensitive window outweighs the cost of a dose that needs fine-tuning in three weeks. Draw a TSH now, before the increase takes full effect, purely as a baseline, and a second one in three to four weeks once the new dose has equilibrated. The number we start on today doesn't have to be the number we end on; it has to be enough not to leave a known-higher-need patient under-covered while we wait for a lab to tell us exactly how much.
Agreed: raise her dose today to roughly 162 micrograms, draw a baseline TSH now, and recheck in three to four weeks to fine-tune from there.
Not agreed: whether thirty percent was the right starting number or an overcorrection. The endocrinologist would have started closer to a forty percent increase given the athyreotic subgroup data specifically; the maternal-fetal medicine specialist preferred the more conservative end of the range precisely because no baseline pregnancy TSH existed yet to justify going higher. The three-to-four-week recheck was set explicitly to resolve that disagreement with data rather than argue it further today.